{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-102394","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.581612+00:00","generated_at":"2026-05-17T20:46:57.002132+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Iterum reports Q2 net loss $6.5M; ORLYNVAH launch on track for August 2025","bullets":["Net loss $6.5M (non-GAAP $5.1M) vs $5.0M prior year; cash $13.0M at June 30, 2025.","ORLYNVAH™ launch expected by end of August 2025 for uUTIs; first oral penem approved in U.S.","Entered commercialization agreement with EVERSANA; hired Christine Coyne as CCO.","Pfizer extended $20M milestone payment deferral to October 2029.","Canadian patent issued covering sulopenem/probenecid combination, expiring 2039."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-102394","json":"https://secwatch.observer/filing/0000950170-25-102394.json","markdown":"https://secwatch.observer/filing/0000950170-25-102394.md","text":"https://secwatch.observer/filing/0000950170-25-102394.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025102394/0000950170-25-102394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025102394/itrm-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:46:57.002132+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}